Understand the source comparison
Pe-22-28 TREK-1 Potassium Channel Blockade: Mechanism Comparison
Comparing Pe-22-28's mechanism with other cognitive enhancement compounds clarifies where TREK-1 blockade fits in the neuroplasticity toolkit. And where it doesn't. Pe-22-28 TREK-1 potassium channel blockade TREK-1 (K2P2.1) two-pore domain K+ channel 30–90 min
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Comparing Pe-22-28's mechanism with other cognitive enhancement compounds clarifies where TREK-1 blockade fits in the neuroplasticity toolkit. And where it doesn't.
- Pe-22-28
- TREK-1 potassium channel blockade
- TREK-1 (K2P2.1) two-pore domain K+ channel
- 30–90 minutes (acute)
- Depolarizes resting membrane → enhances NMDA receptor activation → increased LTP magnitude
- Highly selective ion channel modulation with direct plasticity effects; limited by blood-brain barrier penetration when administered systemically
- Cholinesterase Inhibitors (Donepezil)
- Acetylcholinesterase enzyme inhibition
- Synaptic acetylcholine elevation
- 2–6 weeks (chronic)
- Indirect: increased cholinergic tone modulates attention and encoding; does not directly alter LTP threshold
- Standard-of-care for Alzheimer's but modest cognitive gains in healthy populations; targets neurotransmitter availability, not plasticity mechanisms
- NMDA Modulators (D-Cycloserine)
- Partial agonist at NMDA glycine site
- NMDA receptor GluN1 subunit
- Single dose (context-dependent)
- Facilitates NMDA receptor opening during synaptic activity → enhanced calcium influx
- Effective when paired with learning tasks; minimal effect without concurrent training. Mechanism requires active synaptic input
- AMPA Potentiators (Ampakines)
- Positive allosteric modulation of AMPA receptors
- AMPA-type glutamate receptors
- 1–3 hours (acute)
- Prolongs AMPA receptor open time → larger EPSP → increased likelihood of reaching LTP threshold
- Directly enhances excitatory transmission; risk of excitotoxicity at high doses limits therapeutic window
- HGF Receptor Modulators (Dihexa)
- Hepatocyte growth factor receptor binding
- c-Met receptor tyrosine kinase
- Days to weeks (chronic)
- Activates synaptogenic signaling cascades → dendritic spine formation and stabilization
- Promotes structural plasticity rather than acute functional changes; longer timescale for observable effects
- The table reveals a fundamental distinction: Pe-22-28 alters the electrical excitability state of neurons, creating a permissive environment for plasticity without directly interacting with glutamate receptors or neurotransmitter systems. This positions it as a potential adjunct to learning-based interventions. The channel blockade lowers the threshold for synaptic change, but the directional content of that change still depends on the pattern of synaptic input.